Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
- 24 October 2014
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 50 (18), 3206-3211
- https://doi.org/10.1016/j.ejca.2014.10.007
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during pubertyHaematologica, 2012
- Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV TrialJournal of Clinical Oncology, 2011
- Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinibHaematologica, 2009
- Growth deceleration in a girl treated with imatinibInternational Journal of Hematology, 2009
- International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)Blood, 2008
- Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during pubertyThe Lancet, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Altered Bone and Mineral Metabolism in Patients Receiving Imatinib MesylateNew England Journal of Medicine, 2006
- Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibBlood, 2005
- CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion ProteinsBlood, 1997